Identification of Heritable CTEPH

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

260 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-12-25

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Some patients who have blood clots come down with a life-threatening condition known as Chronic Thromboembolic Pulmonary Hypertension (CTEPH), which is high blood pressure only in the arteries of the lungs. This study seeks to understand more about the genetics causes of CTEPH by obtaining blood samples and examining family histories.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Family Blood Pressure Program - GenNet Network

NCT00005268

Cardiovascular Diseases Heart Diseases Hypertension

COMPLETED

National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension

NCT01907295

Pulmonary Arterial Hypertension

UNKNOWN

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

NCT05584722

Idiopathic Pulmonary Arterial Hypertension Heritable Pulmonary Arterial Hypertension Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo +1 more

RECRUITING

Molecular Epidemiology of Essential Hypertension

NCT00005377

Cardiovascular Diseases Heart Diseases Coronary Disease +1 more

COMPLETED

Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions

NCT02691689

Heart Defects, Congenital Pulmonary Arterial Hypertension Genetic Testing

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project proposes to identify a cohort of Utah patients with CTEPH, and to perform a comprehensive analysis of family history and CTEPH risk factors in these patients, and in controls with acute pulmonary embolism (PE) and pulmonary arterial hypertension (PAH). Detailed family history interviews will be performed with all patients, and all enrolled patients will provide a blood sample for thrombophilia testing and for gene sequencing with the goal of identifying novel genetic variants that contribute to CTEPH risk.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Thromboembolic Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Blood Draw

Intervention Type OTHER

Pulmonary Embolism (PE)

Blood Draw

Intervention Type OTHER

Pulmonary Arterial Hypertension (PAH)

Blood Draw

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Draw

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CTEPH cohort:

1. Confirmed CTEPH based on having undergone PEA surgery.
2. Strongly suspected CTEPH based on right heart catheterization data showing mPAP\>26 and PCWP\<15, and imaging demonstrating chronic thromboembolic disease (either ventilation/perfusion scan, CT pulmonary angiography, or conventional pulmonary angiography).
* PE cohort:

1. PE diagnosed by CT pulmonary angiography or ventilation/perfusion scan within the preceding 24 months.
2. No evidence of PH at the time of enrollment (based on absence of dyspnea, exertional chest pain, or exertional presyncope on history, lack of physical exam findings of PH or right heart failure, and lack of signs of PH on objective data including echocardiography and/or right heart catheterization).
3. No evidence of chronic thromboembolic disease at the time of enrollment (based on chronic appearing thrombus on CT pulmonary angiography or conventional pulmonary angiography, or based on prior high probability ventilation/perfusion scan showing a similar pattern of perfusion defects).
* PAH cohort:

1. Diagnosis of group 1 PAH.
2. Prior normal or low probability ventilation/perfusion scan.
3. No reported history of prior VTE events.
4. If available, all prior evaluations for VTE (including CT pulmonary angiography and Doppler ultrasound exams) must also be negative.